Table 2 Barriers to use of MgSO4 for fetal neuroprotection (N (%) responses for all responses that relate to barriers)
Nodes | Sub-nodes | e-learning module (N = 119) | Site visits (N = 92) | Barriers & Facilitators Survey (N = 147) |
|---|---|---|---|---|
Individual-level | 51 (42.9Â %) | 47 (51.1Â %) | 86 (58.5Â %) | |
 Unsupportive attitudes and beliefs | 12 (10.1 %) | 3 (3.3 %) | 12 (8.2 %) | |
 Not within provider’s control | 4 (3.4 %) | 0 | 2 (1.4 %) | |
 No experience | 3 (2.5 %) | 1 (1.1 %) | 3 (2.0 %) | |
 Inadequate knowledge and understanding | Overall | 15 (12.6 %) | 18 (19.6 %) | 35 (23.8 %) |
 In self | 0 | 3 | 18 | |
 In others | 13 | 4 | 9 | |
 Unclear who lacks knowledge | 2 | 11 | 8 | |
 Forgetting to administer MgSO4 | 1 (0.8 %) | 1 (1.1 %) | 3 (2.0 %) | |
 Fears | Overall | 14 (11.8 %) | 16 (17.4 %) | 13 (8.8 %) |
 Legal | 0 | 2 | 3 | |
 Medication error | 0 | 2 | 0 | |
 Adverse effects of withholding MgSO 4 | 0 | 3 | 5 | |
 Adverse effects of MgSO 4 | 14 | 9 | 5 | |
 Failure to implement guidelines | 0 | 1 (1.1 %)) | 4 (2.7 %) | |
 Evidence concerns (sufficiency and validity) | 2 (1.7 %) | 7 (7.6 %) | 14 (9.5 %) | |
Institutional-level | 64 (53.8Â %) | 34 (37.0Â %) | 40 (27.2Â %) | |
 Unsupportive institutional culture | 2 (1.7 %) | 3 (3.3 %) | 3 (2.0 %) | |
 Timing and transport | 20 (16.8 %) | 17 (18.5 %) | 6 (4.1 %) | |
 Resource constraints | 31 (25.2 %) | 12 (13.0 %) | 20 (13.6 %) | |
 Policy development and implementation | 11 (9.2 %) | 2 (12.0 %) | 11 (7.5 %) | |
Social-level | 4 (3.4Â %) | 11 (12.0Â %) | 21 (14.3Â %) | |
 Lack of provider-institutional consensus | 1 (0.8 %) | 4 (4.3 %) | 15 (10.2 %) | |
 Inadequate interprovider communication | 0 | 7 (7.6 %) | 5 (3.4 %) | |
 Educating patients | 3 (2.5 %) | 0 | 1 (0.7 %) | |